Blockade of protease-activated receptor- 4(PAR4) provides robust antithrombotic activity with low bleeding

Science Translational Medicine

Volumn 9, Issue 371, 2017, Pages

  Wong, Pancras C ^a   Seiffert, Dietmar ^a   Bird, J Eileen ^a   Watson, Carol A ^a   Bostwick, Jeffrey S ^a   Giancarli, Mary ^a   Allegretto, Nick ^a   Hua, Ji ^a   Harden, David ^a   Guay, Jocelyne ^b   Callejo, Mario ^b   Miller, Michael M ^a   Lawrence, R Michael ^a   Banville, Jacques ^b   Guy, Julia ^b   Maxwell, Brad D ^a   Priestley, E Scott ^a   Marinier, Anne ^b   Wexler, Ruth R ^a   Bouvier, Michel ^b,c   Gordon, David A ^a   Schumacher, William A ^a   Yang, Jing ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BMS 986120; CLOPIDOGREL; PROTEINASE ACTIVATED RECEPTOR 4; UNCLASSIFIED DRUG; ANTIBODY; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; PROTEASE-ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; HAPLORHINI; HARTLEY GUINEA PIG; HIGH THROUGHPUT SCREENING; MALE; NONHUMAN; OUTCOME ASSESSMENT; RECEPTOR BLOCKING; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CEREBROVASCULAR ACCIDENT; CHEMISTRY; GUINEA PIG; HEK293 CELL LINE; HUMAN; IC50; MACACA FASCICULARIS; METABOLISM; ORAL DRUG ADMINISTRATION; PROTEIN DOMAIN; THROMBOCYTE; THROMBOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES; BLOOD PLATELETS; FIBRINOLYTIC AGENTS; GUINEA PIGS; HEK293 CELLS; HEMORRHAGE; HUMANS; INHIBITORY CONCENTRATION 50; MACACA FASCICULARIS; MALE; PLATELET AGGREGATION INHIBITORS; PROTEIN DOMAINS; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; STROKE; THROMBIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 85010661813     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf5294     Document Type: Article

References (60)

1. J. W. Eikelboom, J. Hirsh, F. A. Spencer, T. P. Baglin, J. I. Weitz, Antiplatelet drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e89S-e119S (2012).
2. S. D. Wiviott, P. G. Steg, Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 386, 292-302 (2015).
3. S. R. Coughlin, Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
4. J. Chen, H. S. Bernstein, M. Chen, L. Wang, M. Ishii, C. W. Turck, S. R. Coughlin, Tethered ligand library for discovery of peptide agonists. J. Biol. Chem. 270, 23398-23401 (1995).
5. T. R. Faruqi, E. J. Weiss, M. J. Shapiro, W. Huang, S. R. Coughlin, Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J. Biol. Chem. 275, 19728-19734 (2000).
6. J. J. McGuire, M. Saifeddine, C. R. Triggle, K. Sun, M. D. Hollenberg, 2-furoyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 agonist. J. Pharmacol. Exp. Ther. 309, 1124-1131 (2004).
7. S. Natarajan, D. Riexinger, M. Peluso, S. M. Seiler, 'Tethered ligand' derived pentapeptide agonists of thrombin receptor: A study of side chain requirements for human platelet activation and GTPase stimulation. Int. J. Pept. Protein Res. 45, 145-151 (1995).
8. D. M. Feng, D. F. Veber, T. M. Connolly, C. Condra, M. J. Tang, R. F. Nutt, Development of a potent thrombin receptor ligand. J. Med. Chem. 38, 4125-4130 (1995).
9. J. Yang, K. Xu, D. Seiffert, Challenges and promises of developing thrombin receptor antagonists. Recent Pat. Cardiovasc. Drug Discov. 5, 162-170 (2010).
10. D. A. Morrow, E. Braunwald, M. P. Bonaca, S. F. Ameriso, A. J. Dalby, M. P. Fish, K. A. Fox, L. J. Lipka, X. Liu, J. C. Nicolau, A. J. Ophuis, E. Paolasso, B. M. Scirica, J. Spinar, P. Theroux, S. D. Wiviott, J. Strony, S. A. Murphy; TRA 2P-TIMI 50 Steering Committee and Investigators, Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404-1413 (2012).
11. P. Tricoci, Z. Huang, C. Held, D. J. Moliterno, P. W. Armstrong, F. Van de Werf, H. D. White, P. E. Aylward, L. Wallentin, E. Chen, Y. Lokhnygina, J. Pei, S. Leonardi, T. L. Rorick, A. M. Kilian, L. H. Jennings, G. Ambrosio, C. Bode, A. Cequier, J. H. Cornel, R. Diaz, A. Erkan, K. Huber, M. P. Hudson, L. Jiang, J. W. Jukema, B. S. Lewis, A. M. Lincoff, G. Montalescot, J. C. Nicolau, H. Ogawa, M. Pfisterer, J. C. Prieto, W. Ruzyllo, P. R. Sinnaeve, R. F. Storey, M. Valgimigli, D. J. Whellan, P. Widimsky, J. Strony, R. A. Harrington, K. W. Mahaffey; TRACER Investigators, Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366, 20-33 (2012).
12. M. T. Nieman, A. H. Schmaier, Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 46, 8603-8610 (2007).
13. M. L. Kahn, M. Nakanishi-Matsui, M. J. Shapiro, H. Ishihara, S. R. Coughlin, Proteaseactivated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103, 879-887 (1999).
14. L. Covic, A. L. Gresser, A. Kuliopulos, Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39, 5458-5467 (2000).
15. W.-f. Xu, H. Andersen, T. E. Whitmore, S. R. Presnell, D. P. Yee, A. Ching, T. Gilbert, E. W. Davie, D. C. Foster, Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. U.S.A. 95, 6642-6646 (1998).
16. C. K. Derian, B. P. Damiano, M. F. Addo, A. L. Darrow, M. R. D'Andrea, M. Nedelman, H.-C. Zhang, B. E. Maryanoff, P. Andrade-Gordon, Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. 304, 855-861 (2003).
17. P. J. S. Chiu, G. G. Tetzloff, C. Foster, M. Chintala, E. J. Sybertz, Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs. Eur. J. Pharmacol. 321, 129-135 (1997).
18. T. M. Connolly, C. Condra, D. M. Feng, J. J. Cook, M. T. Stranieri, C. F. Reilly, R. F. Nutt, R. J. Gould, Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb. Haemost. 72, 627-633 (1994).
19. M. L. Kahn, Y.-W. Zheng, W. Huang, V. Bigornia, D. Zeng, S. Moff, R. V. Farese Jr., C. Tam, S. R. Coughlin, A dual thrombin receptor system for platelet activation. Nature 394, 690-694 (1998).
20. J. R. Hamilton, I. Cornelissen, S. R. Coughlin, Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J. Thromb. Haemost. 2, 1429-1435 (2004).
21. M. M. Mumaw, M. de la Fuente, D. N. Noble, M. T. Nieman, Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. J. Thromb. Haemost. 12, 1331-1341 (2014).
22. K. Ishii, L. Hein, B. Kobilka, S. R. Coughlin, Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J. Biol. Chem. 268, 9780-9786 (1993).
23. M. J. Shapiro, E. J. Weiss, T. R. Faruqi, S. R. Coughlin, Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J. Biol. Chem. 275, 25216-25221 (2000).
24. L. Covic, C. Singh, H. Smith, A. Kuliopulos, Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb. Haemost. 87, 722-727 (2002).
25. A. Mazharian, S. Roger, E. Berrou, F. Adam, A. Kauskot, P. Nurden, M. Jandrot-Perrus, M. Bryckaert, Protease-activating receptor-4 induces full platelet spreading on a fibrinogen matrix: Involvement of ERK2 and p38 and Ca2+ mobilization. J. Biol. Chem. 282, 5478-5487 (2007).
26. G. Soslau, S. J. Goldenberg, R. Class, B. Jameson, Differential activation and inhibition of human platelet thrombin receptors by structurally distinct a-, b- and g-thrombin. Platelets 15, 155-166 (2004).
27. H.-S. Ahn, L. Arik, G. Boykow, D. A. Burnett, M. A. Caplen, M. Czarniecki, M. S. Domalski, C. Foster, M. Manna, A. W. Stamford, Y. Wu, Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 9, 2073-2078 (1999).
28. J. E. Bird, M. R. Giancarli, N. Allegretto, F. Barbera, P. Wong, W. A. Schumacher, M. L. Ogletree, D. Seiffert, Prediction of the therapeutic index of marketed anticoagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis. Thromb. Res. 123, 146-158 (2008).
29. S. M. Seiler, M. S. Bernatowicz, Peptide-derived protease-activated receptor-1 (PAR-1) antagonists. Curr. Med. Chem. 1, 1-11 (2003).
30. P. Savi, J.-M. Herbert, Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin. Thromb. Hemost. 31, 174-183 (2005).
31. R. F. Storey, S. Husted, R. A. Harrington, S. Heptinstall, R. G. Wilcox, G. Peters, M. Wickens, H. Emanuelsson, P. Gurbel, P. Grande, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50, 1852-1856 (2007).
32. S. Husted, H. Emanuelsson, S. Heptinstall, P. M. Sandset, M. Wickens, G. Peters, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27, 1038-1047 (2006).
33. M. Lordkipanidzé, C. Pharand, T. Anh Nguyen, E. Schampaert, D. A. Palisaitis, J. G. Diodati, Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur. Heart J. 29, 2877-2885 (2008).
34. H. M. Judge, R. J. Buckland, A. Sugidachi, J. A. Jakubowski, R. F. Storey, The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 19, 125-133 (2008).
35. M. Holinstat, B. Voss, M. L. Bilodeau, J. N. McLaughlin, J. Cleator, H. E. Hamm, PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation. J. Biol. Chem. 281, 26665-26674 (2006).
36. J. C. Reséndiz, M. H. Kroll, R. Lassila, Protease-activated receptor-induced Akt activation- regulation and possible function. J. Thromb. Haemost. 5, 2484-2493 (2007).
37. C.-C. Wu, S.-Y. Wu, C.-Y. Liao, C.-M. Teng, Y.-C. Wu, S.-C. Kuo, The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br. J. Pharmacol. 161, 643-658 (2010).
38. L. Jiang, C. Xu, S. Yu, P. Liu, D. Luo, Q. Zhou, C. Gao, H. Hu, A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation. J. Thromb. Haemost. 11, 930-940 (2013).
39. S. S. Shakhidzhanov, V. I. Shaturny, M. A. Panteleev, A. N. Sveshnikova, Modulation and pre-amplification of PAR1 signaling by ADP acting via the P2Y12 receptor during platelet subpopulation formation. Biochim. Biophys. Acta 1850, 2518-2529 (2015).
40. A.-K. Wihlborg, L. Wang, O. Braun, A. Eyjolfsson, R. Gustafsson, T. Gudbjartsson, D. Erlinge, ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler. Thromb. Vasc. Biol. 24, 1810-1815 (2004).
41. N. von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schömig, A. Kastrati, A. Schömig, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112, 2946-2950 (2005).
42. P. C. Wong, C. Watson, E. J. Crain, The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys. J. Thromb. Thrombolysis 41, 514-521 (2016).
43. A. J. Leger, S. L. Jacques, J. Badar, N. C. Kaneider, C. K. Derian, P. Andrade-Gordon, L. Covic, A. Kuliopulos, Blocking the protease-activated receptor 1-4 heterodimer in plateletmediated thrombosis. Circulation 113, 1244-1254 (2006).
44. C.-C. Wu, C.-M. Teng, Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur. J. Pharmacol. 546, 142-147 (2006).
45. W. Wen, S. E. Young, M. T. Duvernay, M. L. Schulte, K. D. Nance, B. J. Melancon, J. Engers, C. W. Locuson II, M. R. Wood, J. Scott Daniels, W. Wu, C. W. Lindsley, H. E. Hamm, S. R. Stauffer, Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. Bioorg. Med. Chem. Lett. 24, 4708-4713 (2014).
46. L. Covic, M. Misra, J. Badar, C. Singh, A. Kuliopulos, Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 8, 1161-1165 (2002).
47. J. J. Stampfuss, K. Schrör, A.-A. Weber, Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin. Nat. Med. 9, 1447 (2003).
48. P. Andrade-Gordon, B. E. Maryanoff, C. K. Derian, H.-C. Zhang, M. F. Addo, A. L. Darrow, A. J. Eckardt, W. J. Hoekstra, D. F. McComsey, D. Oksenberg, E. E. Reynolds, R. J. Santulli, R. M. Scarborough, C. E. Smith, K. B. White, Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 12257-12262 (1999).
49. S. Chackalamannil, Y. Wang, W. J. Greenlee, Z. Hu, Y. Xia, H.-S. Ahn, G. Boykow, Y. Hsieh, J. Palamanda, J. Agans-Fantuzzi, S. Kurowski, M. Graziano, M. Chintala, Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem. 51, 3061-3064 (2008).
50. T. Kosoglou, L. Reyderman, R. G. Tiessen, A. A. van Vliet, R. R. Fales, R. Keller, B. Yang, D. L. Cutler, Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 68, 249-258 (2012).
51. L. C. Edelstein, L. M. Simon, C. R. Lindsay, X. Kong, R. Teruel-Montoya, B. E. Tourdot, E. S. Chen, L. Ma, S. Coughlin, M. Nieman, M. Holinstat, C. A. Shaw, P. F. Bray, Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 124, 3450-3458 (2014).
52. B. E. Tourdot, S. Conaway, K. Niisuke, L. C. Edelstein, P. F. Bray, M. Holinstat, Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler. Thromb. Vasc. Biol. 34, 2644-2650 (2014).
53. J. E. Norman, M. R. Cunningham, M. L. Jones, M. E. Walker, S. K. Westbury, R. B. Sessions, S. J. Mundell, A. D. Mumford, Protease-activated receptor 4 variant p.Tyr157Cys reduces platelet functional responses and alters receptor trafficking. Arterioscler. Thromb. Vasc. Biol. 36, 952-960 (2016).
54. J. D. Muehlschlegel, T. E. Perry, K. Y. Liu, A. A. Fox, S. A. Smith, P. Lichtner, C. D. Collard, S. K. Shernan, J. H. Hartwig, S. C. Body, K. M. Hoffmeister, Polymorphism in the proteaseactivated receptor-4 gene region associates with platelet activation and perioperative myocardial injury. Am. J. Hematol. 87, 161-166 (2012).
55. J. Das, S. David Kimball, S. E. Hall, W.-C. Han, E. Iwanowicz, J. Lin, R. V. Moquin, J. A. Reid, J. S. Sack, M. F. Malley, C. Y. Chang, S. Chong, D. B. Wang-Iverson, D. G. M. Roberts, S. M. Seiler, W. A. Schumacher, M. L. Ogletree, Molecular design and structure-activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Bioorg. Med. Chem. Lett. 12, 45-49 (2002).
56. P. Andrade-Gordon, C. K. Derian, B. E. Maryanoff, H.-C. Zhang, M. F. Addo, W.-m. Cheung, B. P. Damiano, M. R. D'Andrea, A. L. Darrow, L. de Garavilla, A. J. Eckardt, E. C. Giardino, B. J. Haertlein, D. F. McComsey, Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298, 34-42 (2001).
57. C. Galés, R. V. Rebois, M. Hogue, P. Trieu, A. Breit, T. E. Hébert, M. Bouvier, Real-time monitoring of receptor and G-protein interactions in living cells. Nat. Methods 2, 177-184 (2005).
58. S. Angers, A. Salahpour, E. Joly, S. Hilairet, D. Chelsky, M. Dennis, M. Bouvier, Detection of b2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. U.S.A. 97, 3684-3689 (2000).
59. P. C. Wong, E. J. Crain, C. A. Watson, J. Hua, W. A. Schumacher, R. Rehfuss, Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb. Haemost. 101, 108-115 (2009).
60. S. Kamisuki, S. Takahashi, Y. Mizushina, S. Hanashima, K. Kuramochi, S. Kobayashi, K. Sakaguchi, T. Nakata, F. Sugawara, Total synthesis of dehydroaltenusin. Tetrahedron 60, 5695-5700 (2004).